Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

bh.com">lhart@abh.com, +1-615-250-3311

Dial in details for the live conference call for investors 14:00 BST/9:00 EDT on October 28, 2011:

UK dial in: 0800-077-8492 or 0844-335-0351
US dial in: 1-866-804-8688 or 1-718-3541175
International dial in: +44-208-996-3900
Password/Conf ID: 280117
Live Webcast: http://www.shire.com/shireplc/en/investors


 


'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 PRC Clinical, a ... Francisco Bay Area, will exhibit and present at the ... on March 25th and 26th in Tel Aviv, ... with Israeli life science companies seeking to conduct U.S. ... services span all phases of human trials, from Phase ...
(Date:3/4/2015)... 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of innovative therapies ... today announced that it will release fourth quarter ... on Monday, March 9th, 2015. AcelRx management will ... Eastern Time (1:30 p.m. Pacific Time) on March ...
(Date:3/4/2015)... 2015 Vegalab announced the acquisition of Ecowin, ... year. As part of the acquisition, Ecowin rebranded itself ... his role as CEO for the company,s Korea operations. ... work alongside Koo and oversee developments at the new ... Koo founded Ecowin in 2008 to ...
(Date:3/4/2015)... , March 4, 2015 ... Paris in December 2011, ,SARAH, ... yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma ... late 2016.   SARAH, a large French ... (hepatocellular carcinoma, or HCC) has completed patient enrolment, exceeding ...
Breaking Biology Technology:PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5
... PRINCETON, N.J., Feb. 27 Pharmasset, Inc.,(Nasdaq: ... Group,s,Second Annual SIGnificant Investment Options in Healthcare Conference ... in New York, NY. Schaefer Price,Pharmasset,s Chief Executive ... Wednesday, March 5, 2008 from 2:00 PM to ...
... Agreement gives ReachBio exclusive North American distribution rights to, ... products for drug ... applications, SEATTLE, Feb. 27 ReachBio LLC (Seattle, ... line of Axiogenesis AG,(Cologne, Germany) to the North American ...
... Access to ZFN Technology To Potentially Improve ... ... SGMO ) today announced that it has entered into a,second ... to include additional targets for potential improvement,of production cell lines using ...
Cached Biology Technology:Pharmasset to Present at Susquehanna's Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th 2ReachBio Partners with Axiogenesis to Distribute Novel Cell-Based Products in North America 2ReachBio Partners with Axiogenesis to Distribute Novel Cell-Based Products in North America 3Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production 2Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production 3
(Date:3/4/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/48tj8z/global_biometrics ) ... Biometrics Market Forecast and Opportunities, 2020" report ... biometric authentication systems is projected to grow at ... The driving forces for this highly competitive ... and constant development in technology. In 2014, government ...
(Date:3/3/2015)... LAKE FOREST, Calif. , March 3, ... ("Company"), the leading provider of advanced cryogenic ... serving markets including immunotherapies, stem cells, cell ... health, and reproductive medicine, today announced the ... Hutchinson Cancer Research Centers, ("Fred Hutch") ...
(Date:3/2/2015)... Calif. , March 2, 2015 ... leading developer of human interface solutions, today announced ... that is designed to enable rapid and secure ... ID™ module for gaming is a turnkey solution ... the ability to quickly integrate fingerprint ID solutions ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
... organisms that feed on each other in the world,s streams ... whether the waterways flood or run dry than the amount of ... report online in the Oct. 14 issue of the journal ... in river systems will be threatened by increased variability in water ...
... global energy demands is the use of Poplar, a ... the most out of Poplar plantations, varieties that are ... or higher yields, for exampleare desired. But do these ... populations of Poplar? In particular, is the genetic makeup ...
... Calif.) A potent drug derived from an evergreen tree ... deadliest form of breast cancer. According to the National Cancer ... U.S. this year. Scientists at UC Santa Barbara, in ... mechanism by which this drug kills cancer cells. The team ...
Cached Biology News:Yale scientist helps pinpoint threats to life in world's rivers 2The risks and benefits of using poplars for biofuels 2UCSB scientists discover inner workings of potent cancer drug 2
6 x Blend of rTth DNA Polymerase and Tli to provide optimized amounts of both 5-3 and 3-5 proofreading activity...
... The IITC Life Science Rotarods are used ... motor coordination or fatigue resistance on mice and ... humane way. Extremely user friendly; the animals are ... an animal drops onto the individual sensing platforms ...
... Leukemia Virus Reverse Transcriptase (M-MLV RT) is an ... cDNA synthesis with long messenger RNA templates (>5kb). ... gene of M-MLV and consists of a single ... RNase H activity of M-MLV RT is weaker ...
... determination of digitonin and digoxin. Physical form: Lyophilized ... and 0.06% NaCl Preparation Note: Sodium iodide ... Res. Commun., 19, 755 (1965). Unit Definition: ... phosphorus from ATP per min at pH 7.4 ...
Biology Products: